PDF herunterladen
Hamostaseologie 2021; 41(06): 443-446
DOI: 10.1055/a-1576-4059
Review Article

A Vicious Circle of Clonal Haematopoiesis of Indeterminate Potential and Cardiovascular Disease

Carolin A. Ehlert
1   Department of Cardiology and Angiology I, University Heart Center Freiburg – Bad Krozingen and Faculty of Medicine, University of Freiburg, Freiburg, Germany
,
Ingo Hilgendorf
1   Department of Cardiology and Angiology I, University Heart Center Freiburg – Bad Krozingen and Faculty of Medicine, University of Freiburg, Freiburg, Germany
2   Institute for Experimental Cardiovascular Medicine, University Heart Center Freiburg – Bad Krozingen and Faculty of Medicine, University of Freiburg, Freiburg, Germany
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
   Lizenzen und Reprints

Abstract

Clonal haematopoiesis of indeterminate potential (CHIP) represents a recently identified overlap between cancer and cardiovascular disease (CVD). CHIP develops as a result of certain acquired somatic mutations that predispose to leukaemia, but clinically even more prevalent, associate with increased risk for CVD and CVD-related death. Experimental studies suggest a causal role for CHIP aggravating inflammatory processes in CVD, and recent epidemiologic and genetic studies indicate that classical CVD risk factors may increase the risk of acquiring CHIP driver mutations, thus fuelling a vicious circle. The potential mechanism underlying the associative link between CHIP and CVD and mortality has been the focus of a few recent excellent experimental and observational studies which are summarized and discussed in this concise non-systematic review article. These data support a pathomechanistic view of a spiralling vicious circle in which CHIP aggravates the inflammatory immune response in CVD, and CVD-driven elevated haematopoietic activity promotes CHIP development.

Zusammenfassung

Klonale Hämatopoese von unbestimmtem Potential (CHIP) stellt eine Überschneidung von Krebs- und kardiovaskulären Erkrankungen dar, die erst seit Kurzem Beachtung findet. CHIP entsteht infolge bestimmter erworbener somatischer Mutationen und prädisponiert für die Entwicklung von Leukämien. Aber klinisch häufiger ist die Assoziation mit einem erhöhten Risiko für kardiovaskuläre Erkrankungen und Tod. Experimentelle Studien weisen auf eine kausale Beziehung zwischen CHIP und einem verstärkten Entzündungsprozess bei kardiovaskulären Erkrankungen hin. Epidemiologische und genetische Studien suggerieren umgekehrt, dass die klassischen kardiovaskulären Risikofaktoren das Risiko für die Entwicklung somatischer CHIP-assoziierter Mutationen erhöhen und somit einen Teufelskreis antreiben könnten.

Keywords

clonal haematopoiesis - cardiovascular disease - somatic mutation

Schlüsselwörter

klonale Hämatopoese - kardiovaskuläre Erkrankung - somatische Mutation


Publikationsverlauf

Eingereicht: 06. Juni 2021

Angenommen: 11. August 2021

Artikel online veröffentlicht:
23. Dezember 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Steensma DP, Bejar R, Jaiswal S. et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood 2015; 126 (01) 9-16
    CrossrefPubMedGoogle Scholar
  • 2 Genovese G, Kähler AK, Handsaker RE. et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med 2014; 371 (26) 2477-2487
    CrossrefPubMedGoogle Scholar
  • 3 Arends CM, Galan-Sousa J, Hoyer K. et al. Hematopoietic lineage distribution and evolutionary dynamics of clonal hematopoiesis. Leukemia 2018; 32 (09) 1908-1919
    CrossrefPubMedGoogle Scholar
  • 4 Jaiswal S, Fontanillas P, Flannick J. et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med 2014; 371 (26) 2488-2498
    CrossrefPubMedGoogle Scholar
  • 5 Calvillo-Argüelles O, Jaiswal S, Shlush LI. et al. Connections between clonal hematopoiesis, cardiovascular disease, and cancer: a review. JAMA Cardiol 2019; 4 (04) 380-387
    CrossrefPubMedGoogle Scholar
  • 6 Jaiswal S, Natarajan P, Silver AJ. et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med 2017; 377 (02) 111-121
    CrossrefPubMedGoogle Scholar
  • 7 Mas-Peiro S, Hoffmann J, Fichtlscherer S. et al. Clonal haematopoiesis in patients with degenerative aortic valve stenosis undergoing transcatheter aortic valve implantation. Eur Heart J 2020; 41 (08) 933-939
    CrossrefPubMedGoogle Scholar
  • 8 Dorsheimer L, Assmus B, Rasper T. et al. Association of mutations contributing to clonal hematopoiesis with prognosis in chronic ischemic heart failure. JAMA Cardiol 2019; 4 (01) 25-33
    CrossrefPubMedGoogle Scholar
  • 9 Assmus B, Cremer S, Kirschbaum K. et al. Clonal haematopoiesis in chronic ischaemic heart failure: prognostic role of clone size for DNMT3A- and TET2-driver gene mutations. Eur Heart J 2021; 42 (03) 257-265
    CrossrefPubMedGoogle Scholar
  • 10 Natarajan P, Jaiswal S, Kathiresan S. Clonal hematopoiesis: somatic mutations in blood cells and atherosclerosis. Circ Genom Precis Med 2018; 11 (07) e001926
    CrossrefPubMedGoogle Scholar
  • 11 Fuster JJ, MacLauchlan S, Zuriaga MA. et al. Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice. Science 2017; 355 (6327): 842-847
    CrossrefPubMedGoogle Scholar
  • 12 Sano S, Oshima K, Wang Y, Katanasaka Y, Sano M, Walsh K. CRISPR-mediated gene editing to assess the roles of Tet2 and Dnmt3a in clonal hematopoiesis and cardiovascular disease. Circ Res 2018; 123 (03) 335-341
    CrossrefPubMedGoogle Scholar
  • 13 Rauch PJ, Silver AJ, Gopakumar J. et al. Loss-of-function mutations in Dnmt3a and Tet2 lead to accelerated atherosclerosis and convergent macrophage phenotypes in mice. Blood 2018; 132 (Suppl. 01) 745
    CrossrefPubMedGoogle Scholar
  • 14 Fidler TP, Xue C, Yalcinkaya M. et al. The AIM2 inflammasome exacerbates atherosclerosis in clonal haematopoiesis. Nature 2021; 592 (7853): 296-301
    CrossrefPubMedGoogle Scholar
  • 15 Khetarpal SA, Qamar A, Bick AG. et al. Clonal hematopoiesis of indeterminate potential reshapes age-related CVD: JACC review topic of the week. J Am Coll Cardiol 2019; 74 (04) 578-586
    CrossrefPubMedGoogle Scholar
  • 16 James C, Ugo V, Le Couédic JP. et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434 (7037): 1144-1148
    CrossrefPubMedGoogle Scholar
  • 17 Edelmann B, Gupta N, Schnoeder TM. et al. JAK2-V617F promotes venous thrombosis through β1/β2 integrin activation. J Clin Invest 2018; 128 (10) 4359-4371
    CrossrefPubMedGoogle Scholar
  • 18 Fuchs TA, Brill A, Duerschmied D. et al. Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci U S A 2010; 107 (36) 15880-15885
    CrossrefPubMedGoogle Scholar
  • 19 Wolach O, Sellar RS, Martinod K. et al. Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms. Sci Transl Med 2018; 10 (436) eaan8292
    CrossrefPubMedGoogle Scholar
  • 20 Abplanalp WT, Mas-Peiro S, Cremer S, John D, Dimmeler S, Zeiher AM. Association of clonal hematopoiesis of indeterminate potential with inflammatory gene expression in patients with severe degenerative aortic valve stenosis or chronic postischemic heart failure. JAMA Cardiol 2020; 5 (10) 1170-1175
    CrossrefPubMedGoogle Scholar
  • 21 Abplanalp WT, Cremer S, John D. et al. Clonal hematopoiesis-driver DNMT3A mutations alter immune cells in heart failure. Circ Res 2021; 128 (02) 216-228
    CrossrefPubMedGoogle Scholar
  • 22 Heyde A, Rohde D, McAlpine CS. et al. Increased stem cell proliferation in atherosclerosis accelerates clonal hematopoiesis. Cell 2021; 184 (05) 1348.e22-1361.e22
    CrossrefPubMedGoogle Scholar
  • 23 Bhattacharya R, Zekavat SM, Uddin MM. et al. Association of diet quality with prevalence of clonal hematopoiesis and adverse cardiovascular events. JAMA Cardiol 2021; 6 (09) 1069-1077
    CrossrefPubMedGoogle Scholar
  • 24 Haring B, Reiner AP, Liu J. et al. Healthy lifestyle and clonal hematopoiesis of indeterminate potential: results from the women's health initiative. J Am Heart Assoc 2021; 10 (05) e018789
    CrossrefPubMedGoogle Scholar
  • 25 van Deuren RC, Andersson-Assarsson JC, Kristensson FM. et al. Clone expansion of mutation-driven clonal hematopoiesis is associated with aging and metabolic dysfunction in individuals with obesity. bioRxiv 2021 https://doi.org/10.1101/2021.05.12.443095
    CrossrefPubMedGoogle Scholar
  • 26 Yvan-Charvet L, Pagler T, Gautier EL. et al. ATP-binding cassette transporters and HDL suppress hematopoietic stem cell proliferation. Science 2010; 328 (5986): 1689-1693
    CrossrefPubMedGoogle Scholar